This study sought to retrospectively appraise the incidence and management of restenosis after drug-eluting stent (DES) implantation for unprotected left main (ULM) disease.
Background
The promising role of DES for ULM has been reported. However, no detailed data are available on subsequent restenosis.
Methods
From the total sample of patients with ULM treated with DES, we identified those presenting with angiographic ULM restenosis. The primary end point was the long-term rate of major adverse cardiac events (MACE), that is, death, myocardial infarction (MI), or target lesion revascularization (TLR). We also adjudicated stent thrombosis according to the Academic Research Consortium.
Results
Post-DES restenosis in ULM occurred in 70 of 718 patients (9.7%). Of these, 59 (84.3%) were treated percutaneously (34 [48.6%] with additional DES, 22 [31.4%] with standard or cutting balloons, 2 [2.9%] with rotational atherectomy, and 1 [1.4%] with a bare-metal stent), whereas 7 (10%) patients underwent bypass surgery and 4 (5.7%) were treated medically. In-hospital MACE included no periprocedural MI and only 1 (1.4%) death. After 27.2 Ϯ 15.4 months, MACE occurred cumulatively in 18 (25.7%) patients, with death in 4 (5.7%), MI in 2 (2.9%), and TLR in 15 (21.4%). Patients treated with medical, interventional, and surgical therapy had the following MACE rates, respectively: 50%, 25.4%, and 14.3%. Definite, probable, and possible stent thrombosis occurred in 0 (0%), 1 (1.4%), and 1 (1.4%) patient, respectively.
Conclusions
DES restenosis in the ULM artery can be managed in most cases with a minimally invasive approach, achieving favorable early and late results. Significant unprotected left main disease (ULM) occurs in 5% to 10% of patients undergoing coronary angiography, and since the 1970s, coronary artery bypass grafting (CABG) has been considered its preferred treatment (1) . Balloon-only percutaneous coronary intervention (PCI) for ULM is complicated by early elastic recoil, abrupt closure, and late restenosis. Baremetal stents have improved immediate results, but restenosis with ensuing repeat target lesion revascularization (TLR) or sudden death remain major limitations (2) .
Drug-eluting stents (DES) significantly reduce the risk of restenosis, and in some institutions, it has become common practice to perform PCI with DES for ULM (3, 4) . Despite the relatively common occurrence of DES restenosis in ULM (reaching 10% to 20%), there are no data on the optimal management of such patients. The purpose of this multicenter, international, retrospective study was to assess the outcome of patients with ULM restenosis after PCI with DES.
Methods
Study design and patient population. All consecutive patients with an angiographic diagnosis of significant restenosis (Ͼ50% diameter stenosis at coronary angiography) in the ULM were retrospectively selected after PCI with DES of the ULM (July 2002 to October 2006). All patients were included in the study independent of the subsequent decision for medical, interventional, or surgical treatment. At least 6 months of clinical follow-up beyond the documentation of ULM restenosis was required for inclusion. Subjects with protected left main vessels, defined as the presence of at least 1 patent arterial or venous graft to the left coronary artery, were excluded. Written informed consent was obtained by all patients, and ethical committee approval was obtained for database review.
Interventional procedures and post-intervention medications. Coronary angioplasty and stent implantation during index PCI were performed according to current practice and guidelines. The choice of devices, techniques (including the approach to bifurcation stenting, kissing balloon, and postdilatation), and drug therapy (including glycoprotein IIb/ IIIa inhibitors) for the index procedure was at the cardiologist's choice. After the procedure, all patients were advised to continue lifelong aspirin and either 250-mg ticlopidine twice daily or 75-mg clopidogrel for 6 to 12 months or more. The choice between angiographic and clinical follow-up was at the operator's and referring physician's discretion, but often took into account the patient's preference and comorbidities. Nonetheless, in most cases angiographic follow-up was recommended irrespective of symptoms or signs of ischemia 6 to 12 months after the index PCI. Treatment of restenosis was also completely at the cardiologist's discretion, but usually each case was collectively discussed and the final management decision was based on the patient's symptoms/signs of ischemia, coronary anatomy, surgical risk, PCI feasibility, and overall life expectancy. In case of repeat PCI, the choice of technique and device was also at the interventionist's discretion. End point definitions and follow-up. The primary end point of the study was the occurrence of major adverse cardiovascular events (MACE), that is, death, myocardial infarction (MI), or TLR (defined as repeat PCI or CABG for significant restenosis in the previously stented segment or in the adjacent 5 mm). Diagnosis of MI at follow-up was based on peak of total creatine kinase (CK) Ն2 times the upper limit for normal and a concomitant increase of CK-MB over the upper limit of normal and/or ratio of peak CK-MB/peak total CK Ն0.10 and/or CK-MB Ն3 times Values are mean Ϯ SD or n (%). CABG ϭ coronary artery bypass grafting; PCI ϭ percutaneous coronary intervention.
Angiographic and Procedural Characteristics of the First Procedure in the ULM, Before the Diagnosis of Restenosis* Restenosis in the ULM after PCI with DES occurred in 70 of 718 patients (9.7%). Of these, 5.7% were treated with medical therapy only, 84.3% by repeat PCI, and 10% underwent CABG (Table 1 ). The repeat PCI group was characterized by a trend toward a higher prevalence of diabetes (0% vs. 31% vs. 0%, p ϭ 0.10 at chi-square test) but also by higher ejection fraction (43.0 Ϯ 23.4 vs. 53.9 Ϯ 9.5 vs. 45.0 Ϯ 7.1, p ϭ 0.02 at analysis of variance). Globally, 22.1% of restenoses were diagnosed during routine follow-up angiogram and 30.8% had an admission diagnosis of acute coronary syndrome. Angiographic and procedural characteristics. Angiographic and procedural characteristics of the first procedure in the ULM (before the diagnosis of restenosis) are reported Table 2 .
1134 2009:1131-6 in Table 2 , whereas angiographic and procedural characteristics of the procedure showing the ULM restenosis, that is, the index procedure for the purpose of this work, are reported in Table 3 . The location of restenosis was not significantly associated with the subsequent management strategy, even if PCI was the most common approach in all cases. Specifically, distal ULM disease was managed by PCI in 84.1%, by CABG in 9.1%, and by medical therapy in 6.8%, whereas ostial or shaft disease was managed by PCI in 84.6%, by CABG in 3.9%, and by medical therapy in 11.5% (p ϭ 0.839 at chi-square test comparing distal versus nondistal location). Among the 59 patients treated interventionally (repeat PCI group), 57.6% underwent a new DES implantation. In contrast to the previous baseline procedure, paclitaxel-eluting stents were used predominantly (60.6%), followed by sirolimus-eluting stents (39.4%). Among the 70 restenotic patients, CABG was performed only for in-stent restenosis with no case of CABG for disease progression elsewhere.
In-hospital and long-term outcomes. The immediate outcome was quite favorable ( Despite the increasing frequency of ULM restenotic cases in clinical practice (as it occurs in up to 16.7% of subjects treated with DES in the ULM) (7) and its important clinical impact, ULM restenosis after PCI with DES has been incompletely characterized. The present retrospective nonrandomized study is the first to evaluate the outcome of such patients. Our major findings evaluating 70 restenotic cases of 718 initial ULM patients are 2-fold: 1) significant ULM DES restenosis is often characterized by a stable clinical condition; and 2) after 24 months of clinical follow-up from
In-Hospital and Long-Term Follow-Up Events Table 4 In-Hospital and Long-Term Follow-Up Events Values are mean Ϯ SD or n (%). *Defined as ULM and/or ostial left anterior descending and/or ostial left circumflex and/or ostial ramus revascularization. Abbreviations as in Table 2 .
